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Abstract
Background: Lymphovascular invasion (LVI) is an important step in the metastatic cascade; tumor cell migration
and adhesion to blood and lymphatic vessels is followed by invasion through the vessel wall and subsequent
systemic spread. Although primary breast cancers and melanomas have rich blood vascular networks, LVI is
predominately lymphatic in nature. Whilst the adhesion of tumor cells to blood endothelium has been exten-
sively investigated, there is a paucity of information on tumor cell adhesion to lymphatic endothelium.
Methods and Results: Breast cancer (MDA-MB-231 and MCF7) and melanoma (MeWo and SKMEL-30) cell
adhesion to lymphatic (hTERT-LEC and HMVEC dLy Neo) and blood (HUVEC and hMEC-1) endothelial cells
were assessed using static adhesion assays. The effect of inflammatory conditions, tumor necrosis factor-a
(TNF-a) stimulation of endothelial and tumor cells, on the adhesive process was also examined. In addition,
the effects of TNF-a stimulation on tumor cell migration was investigated using haplotaxis (scratch wound)
assays. Breast cancer and melanoma cells exhibited higher levels of adhesion to blood compared to lymphatic
endothelial cells ( p < 0.001). TNF-a stimulation of endothelial cells, or of tumor cells alone, did not significantly
alter tumor–endothelial cell adhesion or patterns. When both tumor and endothelial cells were stimulated with
TNF-a, a significant increase in adhesion was observed ( p < 0.01), which was notably higher in the lymphatic
cell models ( p < 0.001). TNF-a-stimulation of all tumor cell lines significantly increased their migration rate
( p < 0.01).
Conclusions: Results suggest that metastasis resultant from lymphatic vessel-tumor cell adhesion may be
modulated by cytokine stimulation, which could represent an important therapeutic target in breast cancer and
melanoma.
Introduction
Tumor progression to invasive metastatic disease is amajor contributing factor to patient mortality. The pro-
cess of metastasis requires cells to escape from the primary
tumor in a process that often begins with blood and lymphatic
vessel invasion.1 We have shown, in breast cancer, that al-
though a rich blood vascular network is present, vascular
invasion occurs predominantly via lymphatic vessels (96.4%)
as opposed to blood vessels (3.5%).2 We have also shown
similar results in melanoma, in which 85.5% of total invasion
is via lymphatic vessels.3 Biologically, this process requires
the tumor cells to migrate toward a blood or lymphatic vessel,
followed by tumor cell adhesion and invasion through the
vessel. The frequency and occurrence of this process is de-
pendent upon vessel type, and may be due to the presence or
absence of basement membrane, supporting structures, and
the thickness of the vessel wall.4,5 However, other regulatory
mechanisms may also operate.
In vitro, endothelial cell monolayers have been used as a
model system to investigate tumor–endothelial interactions to
mimic interactions that occur in vivo. Current knowledge of
tumor–endothelial interaction is largely derived from studies
using blood endothelial cells (BEC). These studies use a range
of endothelial cells to investigate tumor cell adhesion; how-
ever the most widely used cell type are large vein endothelial
cells from human umbilical cords (HUVEC).6–11 In addition to
HUVEC, humanmicrovascular endothelial cells (hMEC) have
also been used to study tumor–endothelial interactions. The
pro-inflammatory cytokines, tumor necrosis factor-alpha
(TNF-a) and interleukin 1-beta (IL1-b), have been shown to
increase adhesion of pancreatic carcinoma cells to hMEC.12
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Adhesion of melanoma cell lines; MeWo, SKMEL-28, JPC298
and HT144 to human dermal microvascular endothelial cells
(hDMEC) has also been investigated.13
In contrast to blood endothelium, mechanisms underlying
the adhesion of tumor cells to lymphatic endothelium are
still poorly understood. Only a limited number of studies
have utilized lymphatic endothelial cells (LEC), primarily
due to the lack of molecular tools capable of specifically
distinguishing LEC from BEC. Studies investigating the in-
teraction between tumor and lymphatic endothelium have
become possible over the last 10 years, following the dis-
covery of lymphatic-specific markers such as VEGFR-3,14
LYVE-1,15 Prox-1,16 and podoplanin/D2-40.17,18 Studies
utilizing primary LEC have shown an increase in the
attachment of breast cancer cells (MCF7 and MDA-MB-231)
following stimulation with anti-CCL-2 antibody.19 In addi-
tion, the adhesion of MCF7 cells to human microvascular
lung lymphatic endothelial cells (HMVEC-LLy) was reduced
following treatment with an anti-Tn antibody, a common
tumor-associated carbohydrate antigen present in most
carcinomas.20
Studies conducted thus far have utilized either BEC or LEC
to examine tumor–endothelial adhesion. To the best of our
knowledge, no studies have conducted a direct side-to-side
comparison of blood versus lymphatic adhesion. In light of
the importance of lymphatic invasion in the initial metastatic
process, it is important to have a suitable model system to
investigate tumor–lymphatic interactions, which is crucial to
aid our understanding of metastatic dissemination via this
route.
The aim of the current study was to directly compare the
adhesion pattern of breast cancer and melanoma cell lines to
BEC and LEC models (primary and immortalized cell lines).
Furthermore, the stimulatory effect of the cytokine, TNF-a, on
tumor cell adhesion to the endothelial cell models, and on
tumor cell migration was investigated.
Materials and Methods
Cell lines and culture
Endothelial cells. HUVEC were isolated from human
umbilical cords obtained from the Department of Obstetrics,
City Hospital, Nottingham, using the collagenase isolation
technique as described previously.21 Cells from three cords
were pooled to give a single batch of experimental HUVEC.
Cultured flasks were coated with 0.2% gelatin (Sigma, UK)
prior to culture. HUVEC were maintained in 37% nutrient
mixture F-12HAM (Sigma), 3.7% 199media (Sigma), 20% iron
supplemented donor calf serum (PAA Laboratories, Austria),
1% sodiumbicarbonate (Sigma), 14mMHEPES (Sigma), 2mM
L-glutamine (Sigma), 1% penicillin/streptomycin (Sigma),
7.5U/ml heparin (CP Pharmaceuticals, UK), 25 ng/ml epi-
dermal growth factor EGF (Peprotech, UK) and 12.5 ng/ml
basic fibroblast growth factor (bFGF; Peprotech). HUVEC
were used between passage 2 and 6. Human microvascular
endothelial cells (hMEC-1), from ATCC, are an immortalized
human dermal microvascular endothelial cell, immortalized
using SV40 large T-Ag.22 Cells were grown in Endothelial
Basal Medium, EBM (Lonza, USA), 10% iron supplemented
donor calf serum, 1 lg/ml hydrocortisone (Sigma), 10 ng/ml
EGF, and 1% penicillin/streptomycin. Cells were used be-
tween passage 4 and 18. Human telomerase reverse tran-
scriptase immortalized LEC (hTERT-LEC) were a kind gift
from R. Nissato and M. Pepper.23 Cells were used between
passage 27 and 34. hTERT-LEC were cultured in endothelial
EBM with EGM-2 bullet kit (Lonza). Neonatal dermal lym-
phatic microvascular endothelial cells (HMVEC-dLy Neo)
(Lonza), are a primary LEC. The medium for this cell line was
prepared as hTERT-LEC. Cells were used between passage 4
and 6.
Tumor cells. Breast cancer cell lines;MCF7 (used between
passage 23 and 35) and MDA-MB-231 (used between passage
15 and 28) and melanoma cell lines; MeWo (used between
passage 14 and 30) and SKMEL-30 (used between passage 18
and 30), from ATCC, were used in this study. MCF7 and
SKMEL-30 were maintained in RPMI-1640 (Sigma), 10% iron-
supplemented donor calf serum, and 1% penicillin/strepto-
mycin. MDA-MB-231 were maintained in minimal essential
medium (MEM) EAGLE (Sigma), 0.1mM non-essential ami-
no acids (Sigma), 2mM L-glutamine, 1% penicillin/strepto-
mycin, and 1% iron-supplemented donor calf serum. MeWo
were maintained in MEM EAGLE, 10% iron-supplemented
donor calf serum, 2mM L-glutamine, 1% sodium bicarbonate,
0.1mM non-essential amino acids, and 1mM sodium pyru-
vate (Sigma).
Peripheral blood mononuclear cell isolation. Peripheral
blood mononuclear cells (PBMC) were isolated from whole
blood using density-gradient centrifugation method as de-
scribed.24 Bloodwas collected from a consent healthy donor in
a vacutainer tube (BD, UK) containing 170 IU heparin. 2.5ml
histopaque 1119 (Sigma) was added to a 15ml tube to sepa-
rate the granulocytes, followed by histopaque 1077 (Sigma) to
separate the mononuclear cells. 5ml of heparinrized blood
was layered on top of the histopaque 1119 and histopaque
1077 and centrifuged for 30min, 670 g, followed by the re-
moval of PBMC at the second layer. Cells were washed twice
in washing buffer (0.1% bovine serum albumin in phosphate
buffered saline, PBS) and counted by hemocytometer.
Static adhesion assay
Endothelial cells were grown to confluence in a 24-well
plate (seeding density; 0.75 · 105 cells/ml, 1.3 · 105 cells/ml,
1.3 · 105 cells/ml, and 1.5 · 105 cell/ml for HUVEC, hMEC-1,
hTERT-LEC, and HMVEC-dLY cells, respectively). Complete
media was removed and replaced with growth factor-free
media in control wells or growth factor free media supple-
mented with TNF-a (2.5 ng/ml, 5 ng/ml, 10 ng/ml) for 24 h.
PBMCadhesion to endothelial cellswith andwithout TNF-a
stimulation was carried out immediately prior to tumor cell
adhesion experiments to assess immune cell–endothelial cell
interactions, in addition to acting as a control to demonstrate
that the endothelial cells and the cytokine were responding
appropriately. PBMC adhesionwas assessed by adding 4· 105
cells/well for 5min, as this was identified as the optimal assay
time (data not shown). Non-adherent cells were washed from
the endothelial layerwithwashing buffer and assessed visually
by counting adherent cells in the central area of the well using
phase contrast microscopy (10X magnification).
Tumor cell adhesion was assessed following cell labeling
with 1lM Cell Tracker Green CMFDA (Invitrogen, USA) for
30min at 37C. This concentration of Cell Tracker Green was
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determined not to influence cell viability over 72 h (data not
shown). After labeling, tumor cells were resuspended in
RPMI-1640 + 10% iron-supplemented donor calf serum.
0.5 · 105 cells/well were incubated for 35min at 37C on the
different endothelial cell monolayers. 35 minutes was deter-
mined as the optimal adhesion time required for tumor cell
adhesion (data not shown).
Non-adherent cells were washed with RPMI-1640 + 10%
iron-supplemented donor calf serum. Adherent tumor cells
were counted using a fluorescencemicroscope (Nikon, Japan),
in the central area of the well which was marked manually
with grid lines on the bottom of the plate. Two fields of view
were counted in each well (20X magnification). Re-
presentative photomicrographs of tumor cells adhering to
endothelium are shown in Figure 1. Experiments were con-
ducted twice, both in triplicate. Results were expressed as the
absolute number of cells adhered to the endothelial layer and
as the percentage of cells adhered relative to control. In ad-
dition to assessing adhesion to control (unstimulated) and
TNF-a stimulated endothelial cells, assays were also per-
formed under the following conditions: (1) stimulating only
tumor cells with TNF-a (2.5, 5, and 10 ng/ml) and (2) stimu-
lating both endothelial and tumor cells simultaneously with
TNF-a (5 ng/ml). In both conditions, stimulations with TNF-a
were for 24 hours.
Migration assay
Haplotaxis (scratch wound) migration assays, as de-
scribed,25 were conducted with slight modifications. 5 · 105
cells/well (MCF7, MeWo, SkMEL-30) or 4 · 105 cells/well
(MDA-MB-231) were plated in a 12-well tissue culture plate
and incubated for 48 h to ensure a confluent monolayer. 24
hours post-plating, standard culture media was removed and
replaced with growth factor and serum-free media with or
without TNF-a (5 ng/ml) for 24 h. Confluent cell monolayers
were scratched with a pipette tip to create a wound, devoid of
adherent cells. Cell debris was removed by washing twice
with PBS and cells cultured in growth factor and serum-free
media with 10lg/ml of mytomycin-c (Sigma), for the dura-
tion of the assay, to inhibit cellular proliferation. Wound
closure was monitored by photomicrographs at 0, 2, 6, and 24
hours post scratch. The percentage reduction of scratch area at
these time points represented the rate of tumor cell migration
and was measured using ImageJ 1.43u software (National
Institute of Health, USA). Experiments were conducted twice,
each in triplicate.
Statistical analysis
Data are represented as mean– standard deviation of two
independent experiments performed in triplicate. For PBMC
adhesion and tumor cells adhesion under control condition,
data are pooled from 28 independent experiments. The Stu-
dent t-test was used to evaluate variation between control and
TNF-a stimulated condition. P < 0.05 was used to define sig-
nificant relationships. Statistical analysis was carried out
using GraphPad Prism software version 3.02 (GraphPad
Software Inc.).
Results
TNF-a increases PBMC adhesion
PBMC adhesion to unstimulated and TNF-a-stimulated
HUVEC, hMEC-1, hTERT-LEC, and HMVEC-dLy Neo was
conducted immediately prior to tumor cell adhesion
FIG. 1. Representative photomicrographs of tumor cell adhesion. MDA-MB-231 cell adhesion to a hMEC-1 monolayer
observed under phase contrast microscopy (A) and the same field of view using fluorescence (B) at 100X magnification.
MDA-MB-231 cell adhesion to a HUVEC monolayer that was left untreated (C) or stimulated with TNF-a (D), at 200X
magnification.
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experiments to ensure that endothelial cells were responding
as expected. Endothelial cell pre-stimulation with TNF-a for
24 h caused a significant increase in PBMC adhesion com-
pared to the unstimulated controls ( p< 0.01) (Fig. 2). PBMC
adhesion to all endothelial cell models increased with in-
creasing TNF-a concentration and plateaued at 10 ng/ml.
PBMC adhesion to TNF-a-stimulated HUVEC was more than
that to hMEC-1 but was not significantly different ( p > 0.05).
There was no significant difference in the number of cells
adhered to LECmodels, hTERT-LEC, and HMVEC-dLY Neo.
Adhesion of PBMC was significantly higher to stimulated
BEC (HUVEC and hMEC-1) than to LEC (hTERT-LEC and
HMVEC-dLy Neo), ( p< 0.05).
Tumor cells show preferential adhesion to blood
endothelial cells
MCF7, MDA-MB-231, MeWo, and SKMEL-30 showed
similar adhesion patterns to all four endothelial cell models
under control conditions, however with different affinity (i.e.,
greater adherence to blood than to lymphatic endothelium)
(Fig. 3). Of the four tumor cell lines, MDA-MB-231 cells had
the highest affinity towards the BEC,while SKMEL-30 had the
highest affinity towards LEC. Both the breast cancer cell lines
showed relatively less adherence to the LEC than the BEC in
comparison to the melanoma lines. There was no significant
difference in the tumor cell adhesion patterns between pri-
mary and immortalized cell lines of the same origin: blood
and lymphatic.
The percentage adhesion of each tumor cell line to TNF-a-
stimulated HUVEC, hMEC-1, hTERT-LEC, and HMVEC-dLy
Neo was not significantly increased compared to the un-
stimulated endothelial models (Fig. 4). Pre-stimulation of the
tumor cells with TNF-a did not significantly increase their
adhesion to BEC models; except for the adhesion of TNF-a
stimulated MDA-MB-231 to unstimulated HUVEC ( p< 0.001).
However, pre-stimulation of the tumor cell lines with TNF-a
did cause a significant increase of MDA-MB-231, MCF7, and
MeWo cells adhesion to hTERT-LEC ( p< 0.05) (Fig. 5).
As both breast cancer and bothmelanoma cell lines showed
similar adhesion patterns, with similar affinities, double
stimulation experiments using TNF-a were conducted using
MDA-MB-231 and MeWo to study the adhesion patterns to-
wards the immortalized endothelial cell lines hMEC-1 and
hTERT-LEC. When MDA-MB-231 and the endothelial cells
(hMEC-1 and hTERT-LEC) were both simultaneously stimu-
latedwith TNF-a, therewas a significant increase in tumor cell
adhesion to hMEC-1 ( p = 0.02) and hTERT-LEC ( p< 0.001)
(Fig. 6A). The relative percentage of adhered tumor cells was
significantly higher to the LEC compared to the BEC
( p< 0.05). Similar results were also observed with melanoma
where there was a significant increase in adhesion ofMeWo to
hMEC-1 ( p< 0.001) and hTERT-LEC ( p < 0.001); as with the
breast line, the percentage adhesion of MeWo cells were also
higher in the LEC compared to the BEC (Fig. 6B).
TNF-a-stimulation increases the migratory ability
of tumor cells
The effect of TNF-a upon tumor cell migration was also
studied. Tumor cell migration is a prerequisite for metastasis in
addition to tumor cell–endothelial cells adhesion. The migra-
tion of all four tumor cell lines was increased following ex-
posure to TNF-a, which was particularly noticeable with
MDA-MB-231 cells. MDA-MB-231 stimulated with TNF-a had
a significantly higher migration rate compared to the un-
stimulated control at all 2, 4, 6, and 24 hours post wounding
( p< 0.001) (Fig. 7A). MCF7, MeWo, and SKMEL-30 also
showed significantly higher migratory ability at 24 hours post
FIG. 3. Tumor cell adhesion to HUVEC, hMEC-1, hTERT-
LEC, and HMVEC-dLy Neo under control conditions. All
endothelial cell models show the same adhesion pattern with
the 4 tumor cells, MDA-MB-231, MCF7, MeWo, and SKMEL-
30, in which higher adherence to the BEC is observed. The
highest tumor cell adhesion is observed to HUVEC opposed
to hTERT-LEC and HMVEC-dLy Neo. Pooled results from
28 independents experiments, each in triplicate (n = 84).
*significant difference within group, {significant difference
between groups, p< 0.05.
FIG. 2. PBMC adhesion to HUVEC, hMEC-1, hTERT-LEC,
and HMVEC-dLy Neo under control and TNF-a stimula-
tions. Pre-stimulation of endothelial cells with TNF-a caused
a significant increase (*p< 0.01) in the number of PBMC ad-
hered to HUVEC, hMEC-1, hTERT-LEC, and HMVEC-dLy
Neo compared to the unstimulated controls with the highest
adhesion observed to HUVEC. PBMC adhesion to all endo-
thelial cell models increased with increasing concentrations
of TNF-a and plateau at 10 ng/ml. Pooled results from 28
independents experiments, each in duplicate (n = 56). *sig-
nificant difference compared to control group, {significant
difference between groups, p< 0.05.
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wounding; p values< 0.01,< 0.01, and 0.014, respectively
(Fig. 7B–7D).
Discussion
In the present study, the adhesion pattern of breast can-
cer and melanoma cell lines to BEC and LEC models was
compared. PBMC adhesion to unstimulated and TNF-a-
stimulated HUVEC, hMEC-1, hTERT-LEC, and HMVEC-dLy
Neowas also assessed. Adhesion of PBMCwas greater to BEC
than LEC under control conditions. As PBMC were of blood
origin, it may be that they are programmed to interact more
with BEC barrier compared to LEC barrier. PBMC adhesion to
TNF-a stimulated endothelial cells was significantly higher
than the unstimulated controls;26 which may be due to in-
creased expression of adhesion molecules such as ICAM-1
and VCAM-1 in inflammed HUVEC and human dermal LEC
in order to recruit immune cells to the site of inflammation.27–29
The adhesion of PBMC to the endothelial models was used as
internal experimental control prior to the assessment of tumor
cell adhesion to ensure that both cytokine and endothelial cells
were behaving as expected.
The breast cancer, MDA-MB-231 and MCF7, and the mel-
anoma cell lines, MeWo and SKMEL-30, showed different
adhesive affinity towards the endothelial cell models, which
demonstrated the heterogeneous nature of tumor cell adhe-
sion.30 Of the four tumor cell lines, MDA-MB-231 had the
highest affinity towards all endothelial cell models, which
may be related to the highly invasive and aggressive nature of
this tumor cell line.31,32 Although the four tumor cell lines
showed differences in terms of adhesive potential, they all
showed preferential adhesion to BEC opposed to the LEC.
This is interesting in light of observations in breast cancer and
melanoma that show vascular invasion in these tumor types is
principally of lymphatic vessels.2,33,34
Experiments comparing the adhesion of a panel of breast
cancer and melanoma cells to both BEC and LEC have not
previously been reported. However, the preferential adhesion
of colon carcinoma cells, HT29, to lung microvascular endo-
thelial cells (HMVEC), as opposed to large vein endothelial
cells (HUVEC) has been observed.12 This is in contrast to the
current observationsmade using breast cancer andmelanoma
cells, inwhich preferential adhesion of all cell lines,MDA-MB-
231, MCF7, MeWo, and SKMEL-30 was observed to HUVEC
FIG. 4. MDA-MB-231 (A), MCF7 (B), MeWo (C), and SKMEL-30( D) adhesion to TNF-a stimulated HUVEC, hMEC-1,
hTERT-LEC, and HMVEC-dLy Neo at different TNF-a concentrations relative to unstimulated controls. Pre-stimulation of
endothelial cells with TNF-a for 24 hours did not have any significant effect on the adhesion of tumor cells to either BEC
(HUVEC and hMEC-1) or LEC (hTERT-LEC and HMVEC-dLy Neo). Pooled results from two independent experiments, each
in triplicate (n= 6). *significant difference compared to control group, p < 0.05.
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FIG. 5. Adhesion of TNF-a stimulated tumor cells; MDA-MB-231 (A), MCF7 (B), MeWo (C), and SKMEL-30 (D) to un-
stimulated HUVEC, hMEC-1, hTERT-LEC, and HMVEC-dLy Neo. Percentage of tumor cell adhesion to all endothelial cell
lines did not vary significantly under control or stimulated conditions with the exception of MDA-MB-231 adhesion to
HUVEC ( p< 0.001) and the adhesion of MDA-MB-231, MCF7, and MeWo to hTERT-LEC ( p < 0.05). Pooled results from two
independent experiments, each in triplicate (n= 6). *significant difference compared to control group, {significant difference
between groups, p< 0.05.
FIG. 6. The effect on TNF-a double stimulation on the adhesion of MDA-MB-231 (A) and MeWo (B) to hMEC-1 and hTERT-
LEC. Pre-stimulation of both endothelial cell models and the tumor cells caused a significant increase in the percentage of
adhered tumor cells to the endothelial cells with higher adhesion towards hTERT-LEC ( p < 0.001). Pooled results from two
independent experiments, each in triplicate (n = 6). *significant difference compared to control group.
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rather than hMEC-1. These results reflect the diverse nature of
endothelial cells arising from different vascular beds.35,36
There was no difference in tumor cell adhesion to primary
lymphatic cells (HMVEC-dLy Neo) or immortalized lym-
phatic cells (hTERT-LEC), suggesting that despite the im-
mortalization procedure, hTERT-LEC retain a phenotype
similar to the primary cells fromwhich they were derived.23 It
seems, therefore, that hTERT-LEC is a useful in vitromodel to
study lymphatic–endothelial interactions, which can over-
come the problem of the short passage window of primary
lymphatic cells.
The preferential adhesion of cancer cells to BEC rather than
LEC is, in light of results from patient samples,2,3 somewhat
surprising. This may be due to, in tumors, cells being exposed
to inflammatory conditions and associated cytokines. TNF-a
is a multifunctional cytokine that is known to stimulate an-
giogenesis, growth, proliferation, and invasion of tumor cells
via various signaling pathways such as theNF-LB andMAPK
pathway.37,38 Tumor cell adhesion to TNF-a-stimulated HU-
VEC, hMEC-1, hTERT-LEC, and HMVEC-dLy Neo did not
vary significantly when compared to the unstimulated en-
dothelium. Similar results have been described, in which no
significant changes were observed in the adhesion of mela-
noma cell lines; WM9, WM239, and WM119 to unstimulated
and TNF-a-stimulated HUVEC.39 However, others have
shown that tumor cell adhesion increases with TNF-a-stimu-
lation. Colon cancer cells, HT29s, adhere more to TNF-a
stimulated HUVEC and lung microvascular endothelial cells.
The adhesion of breast cancer cells MDA-MB-231 to HUVEC
has been shown to increase approximately six-fold following
TNF-a-stimulation compared to the unstimulated counter-
part.7 No such increase was observed in the current study,
using the same cell models; however both the TNF-a con-
centrations and the incubation time differs between this and
previously published studies.
As the two breast (MDA-MB-231 and MCF7) and the two
melanoma (MeWo and SKMEL-30) cell lines showed similar
adhesion patterns to BEC and LEC, experiments were con-
ducted to examine the effect of TNF-a stimulated MDA-
MB-231 and MeWo cells in influencing the adhesion towards
TNF-a activated hMEC-1 and hTERT-LEC. The significant
increase in tumor cell adhesion when both the tumor and the
endothelial cells were simultaneously stimulated with TNF-a
suggests that dual activation with TNF-a might be necessary
to promote tumor–endothelial cell adhesion. In tumor cells,
TNF-a acts through NF-LB induction of chemokine receptor
CXCR4 and upregulation of molecules such as the monocyte
chemoattractant protein-1 (MCP-1), IL-8, and ICAM-1. In
endothelial cells, TNF-a upregulates various receptors such as
lectin-like oxidized low-density lipoprotein receptor 1 (ox-
LDL receptor 1) or LOX-1.40–43 Interestingly, with TNF-a
stimulation, the adhesion of both MDA-MB-231 and MeWo
was higher to the lymphatic endothelial model (hTERT-LEC),
as opposed to the blood endothelial cells (hMEC-1).
The migration of tumor cells is a prerequisite for metastatic
formation in addition to tumor–endothelial adhesion. There-
fore, we sought to study whether TNF-a had any effect upon
tumor cell migration. TNF-a stimulation altered themigratory
ability of MDA-MB-231, MCF7, MeWo, and SKMEL-30,
which was observed at numerous time points. These
FIG. 7. The effect of TNF-alpha on MDA-MB-231 (A), MCF7 (B), MeWo (C), and SKMEL-30 (D) cell migration. Stimulation
of all tumor cells with this cytokine caused a significant increase in the migratory ability of all four tumor cell lines. MDA-MB-
231 stimulated with TNF-a had a significantly higher migration rate compared to the unstimulated control at 2, 4, 6, and 24
hours post wounding ( p< 0.001). MCF7, MeWo, and SKMEL-30 also showed significantly higher migratory ability at 24
hours post wounding; p value < 0.01,< 0.01, and 0.014, respectively. Pooled data from two independent experiments, each in
triplicate (n = 6). *significant difference compared to control group.
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observations are in agreement with other studies showing
that migration of melanoma and cervical cancer cell lines
(HBL and HW756) was increased with TNF-a-stimulation. A
maximal effect on cell migration on these cell lines was ob-
served between 20 and 24 hours,41,44 duringwhich an increase
in ICAM-145 and integrin46 expression on the tumor cells was
observed.
In summary, translational Immunohistochemical-based
investigations, using human breast tumors and melanomas,
have previously demonstrated that lymphatic vessels play an
important role in the initial metastatic process from the pri-
mary tumour.We have shown that TNF-a-stimulation of both
tumor and endothelial cells causes a significant increase in
tumor cell adhesion, of which the highest increase is observed
on LEC models. Suitable in vitro models are required to fully
elucidate the mechanism(s) regulating lymphovascular inva-
sion, which in some tumor types occurs more frequently to
lymphatics than invasion of blood vessels. The current study
focuses on the adhesion of tumor cells to blood and lymphatic
endothelium, and the migration of tumour cells, following
cytokine stimulation. It will be interesting, in future work, to
examine if such increasedmigration and endothelial adhesion
is paralleled by altered transmigration of tumor cells across
blood and lymphatic endothelium to determine if this is also
preferentially altered with lymphatic endothelial models fol-
lowing cytokine stimulation. Current results suggest that
metastasis resultant from lymphatic vessel–tumor cell adhe-
sion may be modulated by cytokine stimulation, which could
represent an important therapeutic target in breast cancer and
melanoma.
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